Best Cardiac and Vascular Disorders Companies in Japan
The 33 best Cardiac and Vascular Disorders companies in Japan in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Heartseed.
Ranked: Best Cardiac and Vascular Disorders companies in Japan
| # | Company | Disclosed funding | Last round | Stage | Founder | Founded | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Heartseed Developer of myocardial regenerative medicine for treating heart diseases | $77M | 41 mo ago | Public | Keiichi Fukuda Founder & CEO | 2015 | YouTubeBootstrapApache HTTP Server+12 | 71 patents Stem cell-derived cardiomyocyte production, purification, and evaluation technologies | — |
| 2 | Metcela Developer of regenerative biological product for the treatment of heart failure | $37M | 52 mo ago | Series C | Kenichi Nogami Co-Founder & Co-CEO | 2016 | WordPressMySQLPHP+12 | 54 patents Regenerative cell therapies using engineered fibroblasts for cardiac, kidney and lymphatic repair | — |
| 3 | Sound Wave Innovation Medical devices and therapeutic platforms using sound waves | $17M | 5 mo ago | Series C | Hiroaki Shimokawa Founder | 2020 | WordPressApple iCloud MailGoogle Workspace+17 | 18 patents Ultrasonic medical therapy devices and dementia treatment systems using therapeutic ultrasound | — |
| 4 | Cuorips Developer of drug delivery platform for heart failure | $13M | 67 mo ago | Public | Takayuki Kusanagi CEO | 2017 | WordPressMySQLPHP+7 | 25 patents Patents concentrated in health & consumer products | — |
| 5 | Global Vascular Developer of drug eluting stent delivery system for lower limb artery disease | $8M | 16 mo ago | Series B | Shunto Maegawa Co-Founder | 2022 | — | 19 patents Advanced metal alloys for vascular stents and catheter manipulation devices. | — |
| 6 | iHeart Experts in regenerative medicine | $5M | 13 mo ago | Series D | — | 2013 | NginxGoogle Font APISakura Internet+3 | — | — |
| 7 | Cardio Intelligence AI-based medical devices for diagnosis and treatment of heart diseases | $3M | 7 mo ago | Series B | Yuichi Tamura CEO | 2019 | WordPressMySQLPHP+14 | 31 patents Advanced ECG signal analysis and display systems for cardiac diagnostics | — |
| 8 | Adriakaim Provider of treatment devices for acute myocardial infarction patients | $3M | 40 mo ago | Seed | Masatoshi Kobayashi CEO | 2018 | — | — | — |
| 9 | Tokiwa Bio Developer of gene-cell therapies for cancer and chronic diseases | $1M | 12 mo ago | Series B | — | 2014 | WordPressMySQLPHP+8 | — | — |
| 10 | Luxonus Developer of optical ultrasound diagnostic imaging equipment | $938K | 53 mo ago | Series B | Philip Te President & CEO | 2018 | — | 14 patents Medical imaging: advanced image processing and photoacoustic acoustic measurement technologies | — |
| 11 | Terumo Medical Provider of a portfolio of medical devices for interventional cardiology | — | 124 mo ago | Funding Raised | — | 1921 | DrupalPHPVideoJS+25 | — | — |
Top 12 Cardiac and Vascular Disorders companies in Japan
#1
Series C · Chuo City, Tokyo · founded 2020 · 4 employees$17Mraised▾
Medical devices and therapeutic platforms using sound waves. It is a medical device startup that aims to implement low-invasive therapeutic platform technology.
- May 2026Series C$17M
#2
Series B · Minato City, Tokyo · founded 2019$3.2Mraised▾
AI-based medical devices for diagnosis and treatment of heart diseases. The company has developed an automated analysis system that assists healthcare professionals in clinical decision support and treatment. The device diagnoses the heart conditions by analyzing the ECG waveforms and creating a model using deep learning techniques.
- Mar 2026Series B—
- Nov 2025Series B—
- Mar 2024Series A—
- Aug 2022Series A$3.2M
#3
Series D · Kyoto, Kyoto · founded 2013 · 10 employees$5.4Mraised▾
iHeart focuses on developing regenerative medicinal products from iPSC cells for heart diseases which would replace transplantation in case of heart failures. The technology the company uses developed by Prof. Jun K Yamashita of Center for iPS cell Research and Application (CiRA) of Kyoto University.
- Sep 2025Series D$5.4M
- Jul 2021Series C—
- Sep 2014Seed—
#4
Series B · Tokyo, Tokyo · founded 2022$8Mraised▾
Developer of drug eluting stent delivery system for lower limb artery disease. The company's device is equipped with BIOZONE Coating technology, a nanotechnology that suppresses thrombus adhesion and release of harmful nickel ions in the body enabling the endovascular treatment for patients.
- Jun 2025Series B$6.9M
- Dec 2023Series A—
#5
Series B · Tsukuba, Ibaraki · founded 2014 · 10 employees$1.5Mraised▾
TOKIWA-Bio is involved in developing gene-cell therapies for treating cancer and chronic diseases. Their pipeline includes stealth RNA vector (SRV)-based gene-cell therapies, focused on hemophilia and ischaemic disease. They are also developing a device which automatically establishes iPS cells from blood monocyte and T-iPS cells from patients with cancer.
- Oct 2025Series B$2.6M
- Nov 2017Series A$1.5M
#6
Public · Shinjuku City, Tokyo · founded 2015 · 12 employees$76.7Mraised▾
Heartseed is developing myocardial regenerative medicine for treating heart diseases. The company is developing regenerative medicines by using human iPS cells. The lead product HS-001 allogeneic iPS cell-derived regenerated myocardium for the treatment of heart failure
- May 2023Series D$14.4M
- Jun 2021Series C$36.5M
- Mar 2020Series B—
- Nov 2019Series B$25.8M
#7
Series C · Kanagawa, kanto · founded 2016 · 7 employees$36.7Mraised▾
Metcela is developing a regenerative biological product for the treatment of heart failure. The company has developed VCAM-1-positive cardiac fibroblasts metcela’s core patented technology that involves a particular population of cardiac fibroblasts, namely VCAM-1-positive cardiac fibroblast.
- Jun 2022Series C$14M
- Jan 2021Series B$12.7M
- May 2020Series B$4M
- Aug 2018Series A$4.7M
#8
Public · Chuo City, Tokyo · founded 2017 · 52 employees$13.2Mraised▾
Developer of drug delivery platform for heart failure. The company has developed proprietary iPS cell-derived cardiomyocyte sheets (a drug delivery platform) for the treatment of heart failure. They grow the sheets and graft them onto the heart to help it beat properly.
- Mar 2021Series A$13.2M
#9
Seed · Hachioji, Tokyo · founded 2018 · 4 employees$3Mraised▾
Provider of innovative treatment devices for acute myocardial infarction patients. It is a medical equipment research and development company that develops innovative medical devices for the treatment of heart diseases, including acute myocardial infarction, and chronic heart failure.
- Jun 2023Seed—
- Aug 2020Seed$3M
#10
Series B · Tokyo, Tokyo · founded 2018$937.7Kraised▾
Developer of optical ultrasound diagnostic imaging equipment. The company is developing optical ultrasonography equipment and services for easy and safe 3D imaging of blood vessels (blood vessels, lymphatic vessels).
- May 2022Series B$937.7K
- Sep 2021Series B—
#11
Funding Raised · Shibuya, Tokyo · founded 1921 · 30207 employees—raised▾
Provider of a portfolio of medical devices for interventional cardiology. It offers a line of medical devices comprising introducer sheaths, guiding sheaths, guidewires, angiographic catheters, coronary catheters, microcatheters, and embolic for various endovascular procedures; veterinary products; and medical devices, such as blood pressure monitors, hypodermics, syringes, winged-needle sets, micro-collection systems, IV catheters, and lancets and capillary blood collection tubes for routine patient care in outpatient and acute care settings.
#12
Late Stage · Tokyo, Tokyo · founded 2000—raised▾
AETAS Pharma is developing therapies for treating heart and kidney diseases. The lead candidate of the company K201, which has a stabilizing effect on ryanodine receptors (a class of intracellular calcium channels) present in the endoplasmic reticulum. It is being investigated for treating atrial fibrillation. The candidate has completed phase I clinical trial.
- 2015PE—
Funding & investor landscape
Notable founders
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.